Tumor size predicts survival in head and neck cancer, study confirms
Researchers validated that the size of a patient's primary tumor is a reliable predictor of survival outcomes across multiple head and neck cancer types. The finding could help oncologists better stratify patients into risk groups and tailor treatment intensity, potentially improving resource allocation in cancer centers.
Originaltitel: External Validation of Pre‐Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy
BACKGROUND: Primary tumor volume (GTVp) is a key prognostic factor in oropharyngeal squamous cell carcinoma (OPSCC) treated with radiotherapy. We aimed to externally validate this association and assess its relevance in other head and neck sites. METHODS: Patients from the RADCURE dataset were analyzed using Cox regression for local failure, progression-free survival (PFS), and overall survival (OS). Subgroup analyses included HPV status, chemotherapy use, and separate evaluations for hypopharyngeal and laryngeal cancers. Model performance was assessed using the concordance index (C-index). RESULTS: Among 1286 OPSCC patients, increasing GTVp was associated with a higher risk of local failure and reduced PFS and OS, consistent across HPV and chemotherapy subgroups. Similar associations were observed in hypopharyngeal (n = 157) and laryngeal (n = 803) cancers. Model performance was strong (C-index up to 0.82). CONCLUSION: Primary tumor volume is a robust prognostic factor across head and neck cancer sites, supporting risk stratification in curative radiotherapy.